App-Quantinova.ai

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

Jorge E. Cortes - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Vodobatinib

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

Andrew M. Brunner - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic myelomonocytic leukemia

Vidaza

Gene Therapy for Fanconi Anemia, Complementation Group a: Updated Results from Ongoing Global Clinical Studies of RP-L102

Agnieszka Czechowicz - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Fanconi anemia

Filgrastim

Ex-Vivo Autologous Stem Cell Gene Therapy Clinical Trial for Mucopolysaccharidosis Type IIIA: Trial in Progress - NCT04201405

Jane L Kinsella - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Mucopolysaccharidosis 3A

Busulfan

Setbp1 Overexpression Acts in the Place of Class-Defining Somatic Mutations to Drive Mouse and Human FLT3-ITD-Mutant AMLs

Suruchi Pacharne - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

oryzanol

Preclinical Investigation of the p53-MDM2 Antagonist Idasanutlin (RG7388) Demonstrates Significant Activity in High Risk Adult Acute Lymphoblastic Leukemia

Hayden L Bell - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

ribose

The Burkitt Lymphoma International Prognostic Index (BL-IPI)

Adam J Olszewski - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Burkitt lymphoma

N/A

Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis

Juan Pablo Alderuccio - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Burkitt lymphoma

N/A

Survival Outcomes for Plasmablastic Lymphoma: An International, Multicentre Study By the Australasian Lymphoma Alliance

Pietro R Di Ciaccio - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lymphomas

N/A

Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2-Mutant Myeloproliferative Neoplasms

Debra Van Egeren - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myeloid neoplasms

N/A

First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Niels W.C.J. Van De Donk - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Outcomes of Adult and Pediatric Patients with Hematologic Malignancies and COVID-19: A Systematic Review and Meta-Analysis of 1847 Patients

Abi Vijenthira - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hematological malignancies

N/A

MP‐AzeFlu improves quality of life of patients with allergic rhinitis: A real‐world study

Van Weissenbruch R - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Allergic rhinitis

Nostril

Risk factors for cow's milk allergy in Europe: EuroPrevall birth cohort

Khaleva E - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anaphylaxis

N/A

Long‐term safety and tolerability of Berotralstat (BCX7353) for Hereditary Angioedema (HAE) prophylaxis: APeX‐S study results

Farkas H - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Hereditary angioedema

BCX7353

Title: Treating Through in Drug Allergy: What do the allergists think about?

Pur Ozyigit L - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

House dust mite allergen‐specific immunotherapy using an adjuvant‐ and allergoid‐based approach in a murine model of allergic asthma

Heldner A - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Implementing drug provocation testing in the assessment and management pathways of reactions to chemotherapy and biological agents

Mart-Garrido J - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Benralizumab efficacy for severe, eosinophilic asthma with a diagnosis of nasal polyposis: Results from the phase IIIb ANDHI trial

Canonica GW - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Asthma

Benralizumab

Supervised feeds: A review of local practice

Baker C - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Filters

45280 Abstracts